Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sorry Chi-Chi ... back to ignore ... no more time for you
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jun 05, 2022 10:02pm
81 Views
Post# 34733019

RE:RE:Sorry Chi-Chi ... back to ignore ... no more time for you

RE:RE:Sorry Chi-Chi ... back to ignore ... no more time for you
StockingUp21 wrote:

Muggy has "ignored" me 2 times already Full of BS.
Now only 8 days and he responding to someone he ignores. Pumpers or paid stock promoters cannot block people because its either part of their job or they need to discedit people who call there BS!! What a liar

 

MrMugsy wrote: Now I have to put you back on "ignore."
The fun and games with kicking your tush in conversation are over.
I will be puting your other personality (Looking4) on the same "ignore" when you figure no one is listening to Chi-Chi.

The big boys and girls are getting ready to play again - time for me to say goodbye.

Bu-bye old friend

: )

 

 



Sorry Stockings - with the number of communications I have on the go - I hear everything that's happening.  It is almost impossible for me to not hear about what's going on ... and ... I have a really big mouth.

Hahaha!  Can't help myself sometimes.

Don't worry - I'm getting better at it - and as more regulars start coming back here ... the trolls get dround out.  Their time is almost up as far as I'm concerned.

None of it really matters - just background noise.  Don't fret !!!

By the way - you make a very lousy troll - that's not a good job for you - not at all !!!!
Hahaha !
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities